Stock Events

Stock Events

Innate Pharma 

€1.8200
101
-€0.08-4.01% Wednesday 07:28

Statistics

Day High
1.82
Day Low
1.82
52W High
1.938
52W Low
1.51
Volume
3,000
Avg. Volume
-
Mkt Cap
203.29M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17SepExpected
Q4 2024
Q2 2025
Q4 2025
Next
-0.31
-0.28
-0.26
-0.24
Expected EPS
-0.25068673824000004
Actual EPS
N/A

Financials

-1,764.51%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
2.79MRevenue
-49.18MNet Income

Analyst Ratings

6.07Average Price Target
The highest estimate is 6.83.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IDD.XETRA. It's not an investment recommendation.
TotalEnergies
22
TTE.PA
Stellantis N.V
14
STLAP.PA
Credit Agricole.
13
ACA.PA
Axa
12
CS.PA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb competes in the immuno-oncology space, offering products that could be in direct competition with Innate Pharma's pipeline, particularly in cancer treatment.
Merck
MRK
Mkt Cap366B
Merck is known for its strong presence in cancer treatment with Keytruda, competing directly with Innate Pharma's oncology focus.
Roche
RHHBY
Mkt Cap334.28B
Roche operates in similar therapeutic areas as Innate Pharma, including oncology, making it a direct competitor in the development of cancer therapies.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca competes in the oncology sector, including collaborations on drugs that could be in competition with Innate Pharma's developments.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad oncology portfolio that competes with Innate Pharma's cancer treatment and research efforts.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, with its focus on oncology and inflammatory diseases, competes in areas of interest to Innate Pharma.
Novartis
NVS
Mkt Cap292.35B
Novartis has a significant presence in the oncology market, directly competing with Innate Pharma's research and drug development.
AMGEN
AMGN
Mkt Cap233.78B
Amgen's focus on innovative therapeutics in oncology and other areas makes it a competitor to Innate Pharma.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals competes in the biopharmaceutical space, focusing on oncology and other areas relevant to Innate Pharma's interests.
Incyte
INCY
Mkt Cap25.21B
Incyte operates in the oncology and inflammation sectors, directly competing with Innate Pharma in the development of treatments for cancer and autoimmune diseases.

About

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
Show more...
CEO
Jonathan E. Dickinson
Employees
163
Country
France
ISIN
FR0010331421
WKN
000A0LCUJ

Listings

XETRA
DE
IDD.XETRA
STU
DE
IDDA.STU
STU
DE
IDD.STU
LSE
GB
0EVI.LSE

0 Comments

Share your thoughts

FAQ

What is Innate Pharma stock price today?▼
The current price of IDD.XETRA is €1.82 EUR — it has decreased by -4.01% in the past 24 hours. Watch Innate Pharma stock price performance more closely on the chart.
What is Innate Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange Innate Pharma stocks are traded under the ticker IDD.XETRA.
What is Innate Pharma market cap?▼
Today Innate Pharma has the market capitalization of 203.29M
When is the next Innate Pharma earnings date?▼
Innate Pharma is going to release the next earnings report on September 17, 2026.
What were Innate Pharma earnings last quarter?▼
IDD.XETRA earnings for the last quarter are -0.31 EUR per share, whereas the estimation was -0.31 EUR resulting in a +0% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Innate Pharma revenue for the last year?▼
Innate Pharma revenue for the last year amounts to 2.79M EUR.
What is Innate Pharma net income for the last year?▼
IDD.XETRA net income for the last year is -49.18M EUR.
How many employees does Innate Pharma have?▼
As of September 06, 2026, the company has 163 employees.
In which sector is Innate Pharma located?▼
Innate Pharma operates in the Health & Wellness sector.
When did Innate Pharma complete a stock split?▼
Innate Pharma has not had any recent stock splits.
Where is Innate Pharma headquartered?▼
Innate Pharma is headquartered in Marseille, France.